Nexthera Capital LP raised its stake in shares of Global Blood Therapeutics Inc (NASDAQ:GBT) by 15.3% during the fourth quarter, Holdings Channel reports. The institutional investor owned 311,516 shares of the company’s stock after buying an additional 41,441 shares during the period. Global Blood Therapeutics accounts for about 2.3% of Nexthera Capital LP’s portfolio, making the stock its 12th largest position. Nexthera Capital LP’s holdings in Global Blood Therapeutics were worth $12,258,000 at the end of the most recent reporting period.
A number of other large investors also recently made changes to their positions in GBT. Point72 Asset Management L.P. grew its holdings in Global Blood Therapeutics by 189.5% during the 3rd quarter. Point72 Asset Management L.P. now owns 2,022,700 shares of the company’s stock valued at $62,805,000 after buying an additional 1,323,934 shares during the last quarter. Perceptive Advisors LLC grew its holdings in Global Blood Therapeutics by 14.7% during the 4th quarter. Perceptive Advisors LLC now owns 4,889,066 shares of the company’s stock valued at $192,384,000 after buying an additional 625,000 shares during the last quarter. RTW Investments LP grew its holdings in Global Blood Therapeutics by 2,186.9% during the 4th quarter. RTW Investments LP now owns 601,683 shares of the company’s stock valued at $23,676,000 after buying an additional 575,373 shares during the last quarter. Citadel Advisors LLC grew its holdings in Global Blood Therapeutics by 161.7% during the 4th quarter. Citadel Advisors LLC now owns 716,611 shares of the company’s stock valued at $28,199,000 after buying an additional 442,828 shares during the last quarter. Finally, Janus Henderson Group PLC grew its holdings in Global Blood Therapeutics by 43.8% during the 3rd quarter. Janus Henderson Group PLC now owns 1,415,558 shares of the company’s stock valued at $43,953,000 after buying an additional 431,325 shares during the last quarter. Hedge funds and other institutional investors own 92.06% of the company’s stock.
In related news, insider Jung Choi sold 3,000 shares of Global Blood Therapeutics stock in a transaction on Monday, December 18th. The stock was sold at an average price of $36.55, for a total value of $109,650.00. Following the transaction, the insider now owns 135,255 shares in the company, valued at $4,943,570.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Perceptive Advisors Llc bought 175,000 shares of Global Blood Therapeutics stock in a transaction that occurred on Tuesday, December 19th. The stock was purchased at an average price of $38.00 per share, for a total transaction of $6,650,000.00. The disclosure for this purchase can be found here. Insiders sold 54,911 shares of company stock worth $3,059,552 in the last quarter. 5.30% of the stock is owned by insiders.
Shares of Global Blood Therapeutics Inc (NASDAQ:GBT) opened at $54.05 on Tuesday. Global Blood Therapeutics Inc has a fifty-two week low of $24.02 and a fifty-two week high of $68.05. The stock has a market capitalization of $2,689.70, a price-to-earnings ratio of -19.65 and a beta of 4.31.
Global Blood Therapeutics (NASDAQ:GBT) last posted its quarterly earnings data on Tuesday, February 27th. The company reported ($0.94) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by ($0.22). research analysts forecast that Global Blood Therapeutics Inc will post -3.61 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This piece was first posted by Ticker Report and is the property of of Ticker Report. If you are accessing this piece on another website, it was copied illegally and reposted in violation of international trademark and copyright laws. The correct version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3259934/nexthera-capital-lp-has-12-26-million-holdings-in-global-blood-therapeutics-inc-gbt.html.
About Global Blood Therapeutics
Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).
Want to see what other hedge funds are holding GBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Global Blood Therapeutics Inc (NASDAQ:GBT).
Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.